uniQure N.V.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Matthew C. Kapusta
- Full Time Employees
- 221
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Paasheuvelweg 25 Amsterdam NH Netherlands 1105 BP
- IPO Date
- Feb 5, 2014
- CIK
- 0001590560
- Website
- uniqure.com
- Similar Companies
- Business
- uniQure N.V. uniQure N.V. (NASDAQ: QURE) is a biopharmaceutical company focused on gene therapy, developing and commercializing adeno-associated virus (AAV)-based treatments for patients with severe genetic diseases including hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and cardiovascular conditions. Founded in 1998 and headquartered in Amsterdam, the Netherlands, with manufacturing in Lexington, Massachusetts, the company operates globally across the United States, Europe, and other regions, targeting rare disorders through its proprietary viral vector platform that enables potentially curative, one-time administered therapies. Its approved product, HEMGENIX (etranacogene dezaparvovec), addresses hemophilia B and is commercialized via an exclusive global licensing agreement with CSL Behring; the investigational pipeline features AMT-130 for Huntington's disease in late-stage trials with positive three-year topline data reported in 2025, AMT-260 for refractory mesial temporal lobe epilepsy with first patient dosing completed, AMT-162 for ALS, AMT-191 for Fabry disease, and cardiovascular programs in collaboration with Bristol Myers Squibb. Recent developments include a September 2025 refinancing of $50 million debt into a $175 million non-dilutive senior secured term loan facility with Hercules Capital, Inc., extending maturity to 2030 and providing up to $125 million additional funding tied to AMT-130 regulatory and financial milestones to support a potential 2026 U.S. commercial launch; third quarter 2025 financial results highlighted pipeline progress; and ongoing strategic partnerships such as the 2021 CSL Behring deal involving $500 million in payments and a 2023 royalty rights sale for up to $400 million to HealthCare Royalty and Sagard Healthcare.
Company News
uniQure: The Market Graded The Wrong Exam
uniQure N.V. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your QURE Investments
uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review
Cedar Grove Capital Q3 2026 Portfolio Update
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop
uniQure (NASDAQ:QURE) Stock Price Down 5.5% Following Analyst Downgrade
Critical Survey: Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)
uniQure (NASDAQ:QURE) Shares Gap Down on Analyst Downgrade
10 Stocks With Massive Short Squeeze Potential
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
uniQure Plunges on Additional Data From Huntington's Disease Study
uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update
uniQure Stock Crashed on Its Huntington's Data. Wall Street's Price Target Says the Selloff Went Too Far
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing Transcript
uniQure BLA Filed as AMT-130 Shows 4-Year Huntington's Functional Benefit
uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law
QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C.
UniQure Insists Huntington's Drug Is Still on Track as Stock Plunges 48%